Madam Speaker, it is a concern, but as I said in my presentation, every province had opportunities to make those issues known during the negotiations within Canada for CETA. It was done transparently, and every province bought into the process.
I am very aware, having come through the farming community, of the types of generic products that have come forward in the medical field as well. As these become more opportunities for trading, perhaps we will even end up with more pharmaceutical opportunities in the marketplace. It is yet to be determined whether the price of these drugs will go up, as the member has indicated.